Fulgent Genetics (FLGT) Cash & Equivalents (2015 - 2026)

Fulgent Genetics has disclosed Cash & Equivalents across 12 years of filings, most recently posting $23.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $23.4 million, down 65.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.4 million (down 65.22% YoY), and the FY2025 annual result was $50.2 million, down 8.98% from the prior year.
• Cash & Equivalents came in at $23.4 million for Q1 2026 at Fulgent Genetics, down from $50.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $353.1 million in Q1 2022 to a low of $23.4 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $66.2 million (2023), against an average of $84.3 million.
• Across the five-year window, Cash & Equivalents jumped 703.65% in 2022 and slumped 81.26% in 2023, its largest moves.
• Fulgent Genetics' Cash & Equivalents stood at $79.5 million in 2022, then gained by 22.6% to $97.5 million in 2023, then sank by 43.43% to $55.1 million in 2024, then declined by 8.98% to $50.2 million in 2025, then tumbled by 53.38% to $23.4 million in 2026.
• The last three Cash & Equivalents figures came in at $23.4 million (Q1 2026), $50.2 million (Q4 2025), and $117.6 million (Q3 2025), per Business Quant data.